CANY
MNTA

Caxton Associates (New York)’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Caxton Associates (New York)’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-20,659
Closed -$562K – 687
2020
Q1 		$562K Buy
+20,659
New +$575K 0.1% 131

Other funds holding MNTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Caxton Associates (New York)'s MNTA Position: Q2 2020 in Review

Caxton Associates (New York) sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q2 2020, closing a stake of 20,659 shares — an estimated $562K sold.

Caxton Associates (New York) first reported a position in MNTA in Q1 2020 and held it in 1 quarter. The position peaked at $562K in Q1 2020. 237 funds tracked by Wall St. Rank hold MNTA as of Q2 2020.

  • Caxton Associates (New York) reported no remaining Momenta Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
  • Caxton Associates (New York) sold 20,659 Momenta Pharmaceuticals, Inc. shares in Q2 2020, an estimated $562K.
  • Caxton Associates (New York) first reported a position in Momenta Pharmaceuticals, Inc. in Q1 2020 and held it in 1 quarter.
  • Caxton Associates (New York)'s Momenta Pharmaceuticals, Inc. position peaked at $562K in Q1 2020.
  • 237 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q2 2020.

Based on Caxton Associates (New York)'s 13F filing for Q2 2020, filed 14 Aug 2020.